Related Experiment Video
Updated: Jan 5, 2026

Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Hemostatic Agents in Critically Ill Patients
Saurabh Kumar Das1, Maheeja Maddi Reddy1, Sumit Ray1
1Department of Critical Care, Artemis Hospital, Gurugram, Haryana, India.
Insights
This study reviews hemostatic agents for critically ill patients. It highlights their role in managing bleeding emergencies in intensive care settings.
Area of Science:
- Critical care medicine
- Pharmacology
- Hematology
Background:
- Critically ill patients often experience coagulopathy and bleeding complications.
- Hemostatic agents are crucial for managing life-threatening hemorrhage in intensive care units (ICUs).
- Understanding the efficacy and safety of these agents is vital for patient outcomes.
Purpose of the Study:
- To provide a comprehensive overview of hemostatic agents used in critical care.
- To discuss the mechanisms of action, indications, and contraindications of various hemostatic agents.
- To evaluate the current evidence supporting the use of hemostatic agents in critically ill patients.
Main Methods:
- Literature review of studies on hemostatic agents in critically ill patients.
- Analysis of clinical trials and observational studies evaluating hemostatic agent efficacy.
- Synthesis of data on patient populations, dosages, and outcomes.
Main Results:
- Hemostatic agents, including procoagulants and antifibrinolytics, demonstrate variable efficacy.
- Early administration and appropriate patient selection are key to successful hemostasis.
- Adverse events associated with hemostatic agents require careful monitoring.
Conclusions:
- Hemostatic agents are indispensable tools in managing bleeding in critically ill patients.
- Further research is needed to optimize the use of hemostatic agents and define specific protocols.
- Personalized approaches considering patient-specific factors are essential for effective hemostasis.
Abstract:
How to cite this article: Das SK, Reddy MM, Ray S. Hemostatic Agents in Critically Ill Patients. Indian J Crit Care Med 2019;23(Suppl 3):S226-S229.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Introduction to Hemostasis
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
Venous Thrombosis IV: Nursing Management
Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

